AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03626623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytal Wound Matrix 1-Layer
Description: Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
Study NCT03626623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
Study NCT02856230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ranger SL DEB
Description: BTK angioplasty using Ranger SL DEB
Study NCT01885143 — intervention group
Intervention type: RADIATION
Intervention: Digital Breast Tomosynthesis
Study NCT00725023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDP© Lamp
Description: TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
Study NCT00725023 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dummy TDP© Lamp
Description: The dummy TDP© heat lamp is an electrical device with the heating element removed.
Study NCT04061915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infographic Intervention
Description: The intervention consists of participants viewing an HIV self-testing infographic.
Study NCT04061915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based HIV self-testing information
Description: The control arm will read paper-based HIV self-testing instructions.
Study NCT02563275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: motion analysis system
Study NCT02563275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study NCT01322360 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Sulfate
Study NCT04019665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MMSE (mini mental state examination)
Description: mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
Study NCT04019665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SAGE (Self-Administered Gerocognitive Exam)
Description: SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
Study NCT04111484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adrenomedullin
Description: Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
Study NCT00884039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anecortave acetate
Description: anterior juxtascleral depot of 15 mg anecortave acetate
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT03889080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI scan of the brain
Study NCT03451552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
Study NCT00884039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg anecortave acetate
Description: anterior juxtascleral depot of 30mg anecortave acetate
Study NCT02182440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recAP
Description: One hour infusions once daily for three days
Study NCT04134208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT scan
Study NCT04134208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT04134208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT scan
Study NCT03240016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV D1
Study NCT03240016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m\^2 D1 and D8
Study NCT04043156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-precision RT
Description: 18 x 2.33 Gy of high-precision RT in 3.5 weeks
Study NCT02838420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
Study NCT02838420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
Study NCT03452878 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aggressive behavior
Description: Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
Study NCT04111484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT02388945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APD
Description: PDGO APD machines used in the PD patients for 8 weeks
Study NCT02388945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAPD
Description: CAPD used in the PD Patients for 8 weeks
Study NCT01661439 — intervention group
Intervention type: DRUG
Intervention: low molecular weight heparin (enoxeparine)
Description: 1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
Study NCT02018328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT02356224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
Study NCT02182440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 hour IV infusion once daily for 3 days
Study NCT02356224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
Study NCT03393546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure
Description: It includes 4 weekly auricular point acupressure treatments.
Study NCT02525341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
Study NCT02525341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and strengthening exercises
Description: A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
Study NCT02525341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General education
Description: One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
Study NCT01879332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration
Study NCT01879332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 3000 mg once daily
Description: Eslicarbazepine acetate 600 mg tablets for oral administration
Study NCT01879332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 3600 mg once daily
Description: Eslicarbazepine acetate 600 mg tablets for oral administration
Study NCT03181568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MolecuLight i:X™ Imaging Device
Description: Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
Study NCT03181568 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound care
Description: Standard wound care of chronic wounds e.g. sampling, debridement, infection control
Study NCT01849380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
Study NCT01849380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
Study NCT03194321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended-Release Oral Capsule
Description: Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
Study NCT00483223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
Study NCT00483223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
Study NCT01085591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-183,315
Study NCT01085591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01085591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT01497132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral drops 30000 IU weekly
Study NCT01497132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00118365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00118365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Given orally
Study NCT00118365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally
Study NCT00118365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00118365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02856503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.
Study NCT02856503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.
Study NCT04430114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms
Description: Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts.
Study NCT01654731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Study NCT01654731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03762824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccination during antirheumatic treatment
Study NCT03762824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccination during antirheumatic treatment
Study NCT00556712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily
Study NCT00556712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study NCT02703584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buseralin
Study NCT02703584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02703584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregnyl
Study NCT02703584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pregnyl
Study NCT02234960 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab will be given according to summary of product characteristics as per clinical practice.
Study NCT00636142 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg body weight, maximal dose 500 mg; intravenous administration
Study NCT00636142 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg body weight, maximal dose 500 mg; intravenous administration
Study NCT02319161 — intervention group
Intervention type: DRUG
Intervention: Calcium channel blocker and beta blocker
Description: The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
Study NCT02193035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microparticle levels
Description: Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
Study NCT02435407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOS
Description: Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
Study NCT02435407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
Study NCT00460759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT00460759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Study NCT02826421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraSert Preloaded Delivery System
Description: Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
Study NCT02826421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTec Preloaded Delivery System
Description: Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
Study NCT02826421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iSert Preloaded Delivery System
Description: Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
Study NCT02826421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monarch III D Manual IOL Delivery System
Description: Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
Study NCT04025502 — intervention group
Intervention type: DEVICE
Intervention: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
Description: The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
Study NCT02185014 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT04290793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg administered as continuous oral once daily from the first day of the study
Study NCT02792855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: snifﬁng Position(place a 7-cm cushion under head )
Description: Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
Study NCT02792855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Head Extension(without cushion)
Description: Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
Study NCT01535898 — intervention group
Intervention type: OTHER
Intervention: MRI scanner with sequence
Description: The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
Study NCT03624283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: Betahistine is used in the treatment of and vertigo.
Study NCT03624283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based vestibular rehabilitation
Description: Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
Study NCT03884842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab/Dupixent
Description: a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
Study NCT03884842 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00057499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-VS01
Description: IBC-VS01
Study NCT00057499 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IBC-VS01 placebo
Description: IBC-VS01 placebo
Study NCT02268708 — intervention group
Intervention type: PROCEDURE
Intervention: Oncological pulmonary resection
Description: Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care